International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 55 No. 1 January 2026, pp. 535-549

The State Of Automated Insulin Delivery System: Research And Challenges. Review

Maged Naser [1], Mohamed M. Nasr [2], Lamia H. Shehata [3]

[1] Mazahmiya Hospital, Ministry of Health, Kingdom of Saudi Arabia, Department of ob/gyn,
[2] Consultant of General and Endoscopic Surgery (MD, FRCS)
[3] Care National Hospital, Department of Radiology
Corresponding Author: Maged Naser

Abstract: Since the discovery of the existence-saving hormone insulin through Dr Frederick Banting in 1921, there had been many integral discoveries and technical breakthroughs which have enabled people residing with type 1 diabetes (T1D) to live longer, more healthy lives. The development of insulin pumps, continuous glucose monitoring (CGM) systems, and automatic insulin delivery (AID) systems have enabled people living with T1D to safely manipulate their glucose, reduce their HbA1c, and improve their normal health and fantastic lifestyles. though, aid systems aren't but designed for absolutely everyone with T1D, and that they perform great during the overnight length while food and workout are not going on. (AID) systems are not fully computerized in that they require the individual using the machine to announce food and exercise to the system to avoid dangerous hyper- or hypoglycemia, respectively.

Keywords : State, Automated Insulin, Delivery System, Challenges.

I. Introduction

The commercialization of automated insulin delivery (AID) used to be solely feasible through considerable support through presents from the NIDDK. This funding has served the undertaking of NIDDK because the AID has enabled stepped forward human fitness by permitting enormous improvements in glucose outcomes for people living with type 1 diabetes (T1D), but there are more paintings to do and NIDDK is main the method on this effort. modern useful resource structures are not absolutely automated in that they still require meal carbohydrates to be introduced to the systems. Exercising can still be a mission for present day useful resource systems, which do now not routinely locate physical hobby or alter dosing to prevent exercise-prompted hypoglycemia. Furthermore, AID has no longer but been absolutely evaluated and specific for all populations of human beings with T1D which includes women at some stage in being pregnant or older adults. In this NIDDK 75 years anniversary assessment, we discover the cutting-edge gaps and challenges with AID while suggesting new areas that provide opportunities for future development.

1. Expectations and Education for Aid Systems

Proper-sized technology expectancies began with continuous glucose monitoring (CGM), which fundamentally shifted the understanding of glycemic tours. wherein human beings previously interpreted 4–8 glucose readings each day, all of sudden 288 data points were available and geared up for consumption. PWD (people with disabilities) needed to discover ways to live with CGM, to recognize the blessings and the drawbacks, and to avoid becoming overwhelmed by facts.[1,2] Early steerage on insulin changes primarily based on actual-time data, which include trend arrows, and retrospective records analysis grew from the NIH–

funded Diabetes research in Children network (DirecNet),[3,4] and JDRF CGM trials,[5] In addition to early medical exercise,[6–8] in the long run culminating in an global guideline.[9] CGM training set the degree for destiny success with AID.

As soon as CGM converted the panorama of diabetes, AID changed a way to traverse it. AID required new concept at the ecological scale: regulatory, payer, endocrinology practice, health facility-level, and person/circle of relatives' engagement—all to simply accept CGM-knowledgeable insulin delivery with reduced consumer-intervention. With every new resource machine, the diabetes network would trip the familiar "hype cycle" of inflated expectancies, discouragement, and plateau of reality.[10] belief have become a middle requirement for both PWD and clinicians, and was once received in a stepwise method, applying first to predictive low-glucose droop, and thereafter to hybrid closed-loop systems. studies showed that faith used to be context-structured (e.g., less difficult at night compared with postprandial), impacted via previous experience with producers, and reliant on perceptions of accuracy and protection.[11] The reality is remarkably steady across gadgets: users want to provide the gadget time to work, discover ways to belief it, and don't attempt to "trick" the machine. regularly PWD should tempo their intervention rather than be overly aggressive with insulin dosing whilst expecting the device to reply.

Whilst expectations and trust capitalize on similarities between systems, education deciphers the variations. The CARES framework evolved out of NIDDK-funded AID research (table 1), lending form to grasp how structures Calculate insulin transport, settings which might be Adjustable, while to Revert to open-loop, vital training, and Sensor/proportion characteristics.[12,13] Clinicians require expertise of which "levers to pull" for most effective treatment consequences in special systems[14–16] and how to assist PWD pick the fantastic device for them. As resource evolves, differences in set of rules specifications can also turn out to be much less relevant, despite the fact that pillars of established education for PWD and clinicians will continue to be paramount, which include schooling round insulin pharmacodynamics.

Table 1. CARES Paradigm for Differentiating Automated Insulin Delivery Systems

C: Calculate	•How does the algorithm calculate insulin delivery? •Which components of insulin delivery are automated (e.g., basal suspensions, basal modulation, high-glucose corrections, food boluses)?
A: Adjust	•How can the user adjust insulin delivery? •Which parameters can be adjusted to influence insulin delivery during automation (e.g., carbohydrate ratios, insulin action time, basal rates, sensitivity factors)? •Which parameters are fixed?
R: Revert	•When should the user choose to revert to open-loop/no automation? •When will the system default to open-loop/no automation?
E: Educate	•What are the key education points for the advanced diabetes device (e.g., essential training, tips and tricks, best practices)?
S:Sensor/Share	•What are the specific characteristics of the sensor used in the AID system (duration of use, accuracy, interference, lag)? •How can sensor glucose and insulin administration information be shared to remote users and health care providers?

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 55 No. 1 January 2026, pp. 535-549

Practical overall performance will unavoidably preserve to chase person and clinician expectancies, and education will remain indispensable to attaining ideal glycemic and consumer-mentioned effects, at the same time as current systems may not realize whether a person will devour pizza for breakfast, future systems will higher handle the venture once they do.

2. Meals and Hybrid Closed Loop

Current automated AID systems are hybrid, requiring carbohydrate content to be "announced" for insulin dose calculation earlier than a meal begins. despite the fact that AID systems appreciably enhance glycemic effects, dealing with postprandial glucose excursions remains tough by virtue of several factors, which include the timing of premeal bolus, correct carbohydrate counting, overlooked meal boluses, and meal fats and protein content material. This need for user enters additionally will increase diabetes burden and negatively affects the excellent of lifestyles. Over time, several strategies have been evolved to triumph over those challenges. One method eliminates an accurate carbohydrate remember requirement. as an alternative, it makes use of a qualitative estimate of carbohydrate content material ("traditional" "extra," or "less") in comparison with a normal meal for the individual.[17,18] different dual-hormonal (insulin and glucagon) algorithms [19] have explored a similar technique. In a small have a look at through Petrovsky et al,[20] 70% of 34 teenagers with T1D reached the yankee Diabetes company HbA1C intention using a useful AID systems and simplified meal bulletins with three preset personalised fixed carbohydrate amounts. A smartwatch application able to detecting eating conduct and alerting the person advanced glycemic consequences through reducing the rate of late/neglected meal boluses. It accelerated (time in range, 70-180 mg/dL) TIR and decreased HbA1C in a small cohort of individuals with T1D.[21] the use of this "detecting gesture app," an resource showed similar TIR while the machine transformed the gestures to carbohydrate content barring requiring a guide bolus.[22] A retrospective analysis confirmed that the phone bolus feature improved the wide variety of boluses by way of the person,[23] which may make contributions to progressed outcomes.

Automatic insulin delivery structures depend specially on the entered carbohydrate content material for bolus dose calculations, at the side of minor changes for deviations from a pre-set target glucose variety. but it's far widely known that meal protein content material has a dose-established impact, and fat content material can boom insulin resistance, cause early hypoglycemia, and past due hyperglycemia.[24] most systems do no longer incorporate meal composition in their insulin dosing models. but some research assessed the impact of nutrient variables on submit-prandial tours in individuals who use AID systems.[25,26] extra advanced algorithms assist with small, ignored meal boluses. In a small outpatient examine of adults with T1D by way of Shalit et al[27] using resource, ignored announcements of up to 20 g of carbohydrates did no longer lower TIR substantially. Present day insulin formulations have a slower onset of movement than endogenous insulin. some studies have in comparison a more fast-acting insulin's effect on postprandial glucose traits within the placing of useful resource, but the findings are inconsistent.[28-34] An alternative method is to apply an accessory treatment, such as pramlintide (an amylin analog), to postpone gastric emptying and decrease glucagon secretion in a closed-loop algorithm to reduce the need for carbohydrate counting. on this study of 30 teenagers and adults with T1D, the insulin plus pramlintide gadget with simple meal announcement completed the non-inferiority margin with only moderate facet consequences.[35] another looks at explored sodium-glucose co-transporter-2 (SGLT2) inhibitors at the side of easy meal bulletins, which used to be also determined to be non-not as good as the carbohydrate counting technique.[36]

In summary, destiny paintings should integrate the referred to techniques, which includes simplifying carbohydrate access, growing ultra rapid-acting insulin system, and creating meal detection algorithms included with meal composition fashions and adjunctive treatments. This method will cause extra personalised and effective diabetes effects, mainly in attaining most desirable postprandial glucose control.

3. Physical Activity and Multi-sign Closed-Loop

Pioneering work on useful resource structures and exercise control has shown that state-of-the-art algorithms should limit hobby-caused hypoglycemia. [37-46] on account of this early work, most modern-day commercially available AID systems have a pastime/workout mode, wherein the goal glucose degree is accelerated above the usual degree and insulin delivery is decreased for the duration of exercise. this will be effective at reducing exercising-associated hypoglycemia throughout various varieties of exercise. [47-52] but, these systems all require user initiation well earlier than exercise. current clinical recommendations on exercise and resource structures advise the usage of higher transient targets in advance of exercise.[53] lamentably, those and different hypoglycemia mitigation techniques are seldom utilized by maximum people with T1D on useful resource who work out often.[54]Studies that version the complexity of glucose and insulin dynamics during bodily activity in T1D have lately been performed that have to enhance on cutting-edge useful resource structures.[55-60] Workout "occasions" can now be detected using industrial merchandise like smartwatches and pastime bands or earrings, which can be integrated into proof-of-thinking AIDs for workout control.[45,61,62] but, those alerts and various interest-knowledgeable algorithms are not but absolutely incorporated into business resource structures for diverse technical and feasibility motives and only a few AID systems with superior workout settings have been examined.[42,43,45,46,63]Activity monitors usually use heart rate photoplethysmography and accelerometry facts to hit upon workout, sleep and stress occasions. some pastime trackers can estimate power expenses throughout every day physical activity, generally reported as metabolic energy equivalents, to estimate workout intensity. These statistics can be in particular precious in emerging useful resource systems as the requirement for insulin modifications nonlinearly with increasing exercise intensities.[64]

Technical and complex physiological demanding situations stay within the development of a useful resource system that automatically responds to bodily interest. The recognized "hurdles" for this include the fast modifications in glucose turnover at some point of exercising, the impact of exercising on insulin pharmacokinetics and pharmacodynamics, and the strange glucagon responses to exercise and/or hypoglycemia in T1D.[65] With extended aerobic exercising, subcutaneous insulin absorption will increase in people with T1D on pump remedy and systemic insulin ranges tend to upward jostle, which increases glucose disposal and limits hepatic glucose production.[66] Vasodilation of the pores and skin and skeletal muscle mass caused by cardio workout increases skeletal muscle glucose oxidation rate even as also growing subcutaneously delivered insulin absorption rate, which contributes to a relative hyperinsulinemia that limits hepatic glucose manufacturing thereby causing a drop in glycemia until carbohydrates are consumed.[67] The blunted glucagon response to exercising in T1D in all likelihood will increase hypoglycemia risk.[68,69] those pharmacokinetic and pharmacodynamic movements of insulin and glucagon at some stage in workout may be overcome through the use of modern dual hormone AID systems normally with version predictive controller (MPC) algorithms which can reduce or droop insulin and infuse glucagon automatically.[70-72] Activity-induced hyperglycemia can result from in depth exercising, resistance education or competition pressure, usually caused by the fast increase in counterregulatory hormones and lactate.[72] Some insulin-only AID systems already can also manipulate publish-workout hyperglycemia nicely.[48,73] proof-of-thought AID systems can now as it should be and routinely distinguish among numerous types of exercising and adjust insulin shipping thus.[74] improving glucose time-in-variety (TIR) outcomes at some point of and following workout can be supported within the future thru use of quicker insulins and AI-enabled precision-medication structures that use pattern recognition and digital twins to provide computerized dosing changes and selection help round exercising.[75]

4. The Synthetic Pancreas in being Pregnant

Pregnancies complicated by pre-current diabetes have an accelerated risk of adverse pregnancy outcomes (APOs), consisting of fetal/neonatal deaths, congenital anomalies, preeclampsia, preterm transport, abnormal fetal outcome, and neonatal morbidity. Tighter glucose goals are required compared to those out of doors being pregnant [76](140 mg/dL pregnant vs 70-180 mg/dL non-pregnant) to reduce APOs. while AID systems use has validated improvements in glycemic results and reduction in the burdens of self-care for people with diabetes, much less studies has focused on the specific needs of being pregnant in individuals with T1D,[77] with even fewer data in those with type 2 diabetes (T2D) converting levels of maternal insulin resistance for the duration of gestation pose glycemic demanding situations.[76,78] The insulin resistance of pregnancy is multifaceted and is prompted by hormonal, placental, genetic, and epigenetic contributions, precise to each pregnant person. Maternal glycemia is also prompted via maternal bodily activity stages, food plan/microbiome, and weight.[79] Together those typically result in changing insulin doses: 20% much less insulin in early gestation, 200-300% more insulin by using delivery, and as much as 50% less insulin post-partum in comparison to pre-pregnancy.[80,81]Imposing useful resource use at some point of pregnancy calls for precise configurations such as: (1) ability to securely obtain the tighter being pregnant time in variety prior to thought and at some point of gestation, (2) set of rules adaptability to adjustments in insulin sensitivity during gestation, (3) assertive put up-prandial insulin transport such as a mechanism

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 55 No. 1 January 2026, pp. 535-549

to reply to changes in glycemia postprandially, (4) more competitive glucose targets except an improved chance of maternal hypoglycemia, and (5) capability to rapidly adapt to adjustments in insulin requirements post-partum (through putting changes and set of rules adaptation).[82]

Moreover, a pregnancy-specific system ought to be person-pleasant, regardless of a man or woman's health care popularity or literacy, to maximise advantages and reduce risks throughout gestation. Use of continuous glucose monitoring (CGM) at some point of pregnancy is related to enhancements in fetal effects for T1D pregnancies. while a few trials have proven improved maternal glycemia with useful resource therapy, none were competently powered to evaluate maternal and/or neonatal health outcomes[83]. So far, solely one resource algorithm has a demonstration to be used all through pregnancy, and only 2 algorithms provide customization to reach the being pregnant glycemic objectives. when those structures are unavailable, many humans combat with whether to use or stop an aid system which met preconception desires. Many pregnant customers of off-label systems, without access to pregnancy-unique structures, use assistive bolusing strategies to increase insulin transport with variable results. Others revert back to CGM with a couple of day-by-day injections or insulin pump shipping with inconsistent results.[84] however, many pregnant women with T1D typically pick the usage of aid remedy, whether or now not it's far specially designed to meet pregnancy desires.[85-87] More research is indispensable to similarly expand and refine therapeutic options to maximise glycemic manipulate, lessen self-care burden, and improve health results previous to idea, during gestation, and into the post-partum period. Further evaluation and appreciation of being pregnant-particular CGM metrics, strategies to achieve better pregnancy-unique time in range to lessen large-for-gestational age babies and other APOs, together with automatic processes to assist pregnancies with T1D and T2D, requires contributions from patients, academia, enterprise partners, and continued AID from the NIH and other funding corporations.

5. The Artificial Pancreas in Older Adults

Older adults with T1D represent a developing population and despite advancements in treatment picks, confined studies accounts owed for the particular characteristics of aging with T1D.[88] challenges in frailty, dexterity, vision, cognition/government functioning amongst other headaches want to be taken into consideration whilst implementing remedy plans.[89] Those co-morbid situations may also affect the uptake and renovation of diabetes-related technology which has proven advanced glycemic effects in other age ranges and yet only emerging facts exist in older adults with T1D.[90,91] In older adults, worries had been raised concerning improved dangers of severe hypoglycemia (SH) and its attendant effects which include falls and fractures, especially in the placing of impaired hypoglycemia awareness with increasing duration of diabetes.[92-95] The WISDM examine of CGM use in older adults with T1D drastically identified unrecognized better rates of hypoglycemia overnight and stated beneficial glycemic effects with CGM use on my own.[96,97] Currently, a randomized controlled examine using CGM more advantageous with geriatric principles including placing appropriate glycemic goals and imposing simplification techniques primarily based on normal health of older adults with T1D, has shown decreased hypoglycemia besides worsening glycemic control in a value-powerful style.[90]

6. The Artificial Pancreas in Type 2 Diabetes

The usage of AID systems in human beings with type 2 diabetes (T2D) is developing, but magnificent evidence from randomized controlled trials in this populace is simply starting to become available. In a 13-week randomized multicenter trial of 319 human beings with T2D, HbA1c reduced through 0.9 percent factors within the aid group in comparison with 0.3 percentage factors in the manipulate group.[98] In (2) single-center crossover trials, the CE marked CamAPS HX absolutely closed-loop machine (no meal announcements) used to be secure and related to increased time in goal variety in comparison with widespread insulin remedy without growing time in hypoglycemia.[99,100] In a multicentre crossover trial regarding adults with T2D using insulin pumps in France, hybrid closed-loop stepped forward time in variety in comparison to insulin pump and sensor barring without increasing hypoglycemia.[101]Data from non-randomized earlier than and after research of hybrid closed-loop systems which include control-IQ, Omnipod 5, and Medtronic MiniMed 780G in adults with T2D have lately been mentioned, however efficacy cannot be decided on account of the shortage of a control organization.[102 -104] actual-international observational information is also available for manage-IQ, which these days obtained FDA acclaim for use in adults with T2D.[105,106]

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 55 No. 1 January 2026, pp. 535-549

Fully-Automated Closed Loop: Clinical and Engineering Perspectives

The closing goal of insulin transport automation for individuals with T1D is to lessen or exclude consumer burden and need to engage with their diabetes devices. The tough project of dealing with postprandial hyperglycemia can in addition be complex by means of late hypoglycemia, mainly due to not on time onset of insulin action. numerous algorithms, on the whole MPC, were explored the use of exclusive meal anticipation and detection techniques primarily based on glucose and insulin data. A sector MPC confirmed promising results in short-time period supervised research going through unannounced meals and exercise[107-113]; a step toward fully closed loop (FCL) therapy was once using adaptive layer to the area-MPC hybrid AID, resulting in a significant reduction in HbA1C following 12 weeks.[114] similarly, a multiple model probabilistic predictive control (MMPPC) that expected meals only while the affected person was once awake[115] established an average CGM fee of 157 mg/dL throughout a hotel examine that blanketed meal and exercising demanding situations.[115,116] artificial talent processes have additionally been used to routinely discover and dose for food. In a small study, Mosquera-Lopez and colleagues advanced a neural network that might routinely detect meals, estimate the meal size, and dose insulin in response to the detected glucose, displaying a 10.8% discount in postprandial time in excessive glucose (< 180 mg/dL).[117]The team at the college of Virginia middle for Diabetes era has developed an adaptative MPC schema designed to characteristic in FCL, displaying sizeable improvement over a current aid device in a supervised look at of 18 adolescents. further enhancements had been proven with automatic priming bolus triggering while meal-like CGM profiles have been detected.[118] furthermore, the MPC may be changed to expect repeating consuming conduct whilst ensuring protection while user behavior trade; though while proven in-silico, postprandial TIR enhancements had been now not obvious in a latest feasibility have a look at.[119,120] domestic studies are at present beneath way (NCT06041971, NCT06633965).

The CamAPS set of rules from Cambridge was tested in adults with T1D and suboptimal glucose control. This FCL notably stepped forward glucose manage without growing the chance of hypoglycemia.[121] further, the device has been proven to improve glycemic manage in complex scientific and surgical inpatients with T2D with challenging glycemic control.[122] Fuzzy-common sense manipulates set of rules DreaMed GlucoSitter gadget with faster Aspart was evaluated in FCL in the course of a double-blind, randomized, crossover trial with 20 participants. there was no huge distinction in glycemic consequences between preferred and faster Aspart arms with workout and meal demanding situations.[123]Evidence suggests adjunctive redress like glucose-like peptide-1 receptor agonists (GLP 1 RAs), GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual receptor, and SGLT2 inhibitors can improve glycemic results and reduce frame weight and insulin requirement.[124-126] Similarly to glucose management, those capsules lower cardiovascular and kidney ailment dangers. these adjunctive remedies may additionally in the end be applied in aggregate with FCL structures, however, the algorithms can also want to be knowledgeable of the adjunctive therapy and altered primarily based at the treatment. Pramlintide, which is an analog of the hormone amylin, delays gastric emptying and when added together with insulin on the time of a meal, can considerably reduce the postprandial glucose spike by means of permitting the insulin kinetics to extra carefully suit carbohydrate absorption prices.[127] In an observe carried out by way of Tsoukas et al,[128] the combination of Fiasp and pramlintide in multi-hormone FCL used to be not located to be non-inferior to a hybrid closed loop system with Fiasp in adults with T1D with suboptimal glucose manage at baseline. The Inreda AP bihormonal (insulin and glucagon) FCL system (Netherlands) was tested in a tribulation with 78 adults with T1D. After 12 months of FCL remedy time in range was accelerated from 55.5% at baseline to 80.3% and median time under variety used to be just 1.36%.[129]

II. Conclusion

Even as the integral help of the NIDDK has enabled the commercialization of the useful resource, there is nonetheless a NEED to hold to improve resource technologies which will assist all populations of human beings dwelling with T1D. next era aid and multi-hormone computerized hormone transport structures will possibly be capable of automatically manage meals without person enter and mechanically stumble on and modify dosing at some point of workout. New useful resource structures are expected to be greater extraordinarily personalized with a purpose to adapt to all people's physiology and the body structure of various agencies of human beings residing with T1D together with being pregnant and older adults. continuing research is ongoing to perceive the pleasant metric, or organization of metrics, for assessment of AID systems inclusive of TIR, time in tight variety (70-140mg/dL), and the way fantastic to implement those to enhance results.[130-133] Future studies ought to examine the value-effectiveness and impact on exceptional-of-lifestyles of utilization of resource by human beings with T1D. a narrative evaluate by Mathieu et al[134] of 18 studies evaluating price effectiveness and quality of life confirmed that almost all studies demonstrated that resource systems were fee powerful and progressed best of lifestyles. artificial talent, adaptive controls, faster insulin, adjunctive medicines, and extra research in greater heterogeneous cohorts might be vital for permitting improvements that can improve performance and glucose results in humans with T1D. We anticipate that the NIDDK will preserve to satisfy its undertaking to improve human health through enabling progressive studies and development efforts to be able to deal with these challenges to offer the subsequent technology of therapeutics to improve fitness in people living with diabetes. Subsequent-generation aid systems will need to help all and sundry, together with older adults, people in the course of being pregnant, athletes, and those who can be too busy to announce carbohydrates or exercise to the machine. solutions are now becoming available as a way to permit aid systems to assist a broader variety of humans residing with T1D by way of leveraging the today's technologies in synthetic Genius and adaptive manipulate. greater studies are required to layout and compare greater shrewd aid structures that do not require accurate carbohydrate estimations or announcements for meals and exercising. modern-dayAID systems also are not designed to be utilized by older adults or pregnant people. Effects are presented on new AID systems that may automatically reply to food and exercising. outcomes also, are provided on reviews of AID systems in older adults and pregnant people.

Abbreviations

Hype Cycle: Gartner's Hype Cycle is a graphical depiction of a common pattern that arises with each new technology or other innovation.

NIDDK: The National Institute of Diabetes and Digestive and Kidney Diseases .

PWD: Stands for Persons with Disabilities.

JDRF: Juvenile Diabetes Research Foundation.

WISDM: Web Information System Development Methodology.

TIR: Time In Range.

SGLT2: Sodium-glucose co-transporter 2.

APOs : Adverse pregnancy outcomes .

Funding

The author(s) declare that no financial support was received for the research and/or publication of this article.

Conflict of Interest

All authors declare no conflicts of interest.

Author Contribution

Authors have equally participated and shared every item of the work.

References

[1]- Pickup, John C., Melissa Ford Holloway, and Kritika Samsi. "Real-time continuous glucose monitoring in type 1 diabetes: a qualitative framework analysis of patient narratives." *Diabetes care* 38.4 (2015): 544-550.

[2]- Hirsch, Irl B. "Realistic expectations and practical use of continuous glucose monitoring for the endocrinologist." *The Journal of Clinical Endocrinology & Metabolism* 94.7 (2009): 2232-2238. [3]- Diabetes Research in Children Network (DirecNet) Study Group. "Use of the DirecNet Applied Treatment Algorithm (DATA) for diabetes management with a real-time continuous glucose monitor (the FreeStyle Navigator)." *Pediatric diabetes* 9.2 (2008): 142-147.

[4]- Messer, Laurel, et al. "Educating families on real time continuous glucose monitoring." *The Diabetes Educator* 35.1 (2009): 124-135.

[5]- Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. "Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial." *Diabetes care* 33.1 (2010): 17-22.

[6]- Evert, Alison, et al. "Continuous Glucose Monitoring Technology for Personal Use." *The Diabetes Educator* 35.4 (2009): 565-580.

[7]- Laffel, Lori M., et al. "A practical approach to using trend arrows on the Dexcom G5 CGM system to manage children and adolescents with diabetes." *Journal of the Endocrine Society* 1.12 (2017): 1461-1476.

[8]- Aleppo, Grazia, et al. "A practical approach to using trend arrows on the Dexcom G5 CGM system for the management of adults with diabetes." *Journal of the Endocrine Society* 1.12 (2017): 1445-1460.

[9]- Battelino, Tadej, et al. "Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range." *Diabetes care* 42.8 (2019): 1593-1603.

[10]- Messer, Laurel H., and Cari Berget. "Hybrid closed-loop systems to date: Hype versus reality." *Diabetes Technology & Therapeutics* 25.1 (2023): 91-94.

[11]- Iturralde, Esti, et al. "Expectations and attitudes of individuals with type 1 diabetes after using a hybrid closed loop system." *The Diabetes Educator* 43.2 (2017): 223-232.

[12]- Messer, Laurel H., Cari Berget, and Gregory P. Forlenza. "A clinical guide to advanced diabetes devices and closed-loop systems using the CARES paradigm." *Diabetes technology & therapeutics* 21.8 (2019): 462-469.

[13]- Messer, Laurel H., et al. "The dawn of automated insulin delivery: a new clinical framework to conceptualize insulin administration." *Pediatric diabetes* 19.1 (2018): 14-17.

[14]- Messer, Laurel H., et al. "Optimizing hybrid closed-loop therapy in adolescents and emerging adults using the MiniMed 670G system." *Diabetes Care* 41.4 (2018): 789-796.

[15]- Castañeda, Javier, et al. "Predictors of time in target glucose range in real-world users of the MiniMed 780G system." *Diabetes, Obesity and Metabolism* 24.11 (2022): 2212-2221.

[16]- Messer, Laurel H., and Marc D. Breton. "Therapy settings associated with optimal outcomes for t: slim X2 with control-IQ technology in real-world clinical care." *Diabetes Technology & Therapeutics* 25.12 (2023): 877-882.

[17]- Russell, Steven J., Edward R. Damiano, and Peter Calhoun. "Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. Reply." *The New England journal of medicine* 388.4 (2023): 380-382.

[18]- Russell, Steven J., et al. "Outpatient glycemic control with a bionic pancreas in type 1 diabetes." *New England Journal of Medicine* 371.4 (2014): 313-325.

[19]- Gingras, Véronique, et al. "A simplified semiquantitative meal bolus strategy combined with single-and dual-hormone closed-loop delivery in patients with type 1 diabetes: a pilot study." *Diabetes technology & therapeutics* 18.8 (2016): 464-471.

[20]- Petrovski, Goran, et al. "Simplified meal announcement versus precise carbohydrate counting in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed loop system: a randomized controlled trial comparing glucose control." *Diabetes Care* 46.3 (2023): 544-550.

[21]- Corbett, John P., et al. "Smartwatch gesture-based meal reminders improve glycaemic control." *Diabetes, Obesity and Metabolism* 24.8 (2022): 1667-1670.

[22]- Roy, Anirban, et al. "An automated insulin delivery system with automatic meal bolus based on a hand-gesturing algorithm." *Diabetes technology & therapeutics* 26.9 (2024): 633-643.

[23]- Messer, Laurel H., et al. "Smartphone bolus feature increases number of insulin boluses in people with low bolus frequency." *Journal of Diabetes Science and Technology* 18.1 (2024): 10-13.

[24]- Paterson, M. A., et al. "Impact of dietary protein on postprandial glycaemic control and insulin requirements in type 1 diabetes: a systematic review." *Diabetic Medicine* 36.12 (2019): 1585-1599.

[25]- Scidà, Giuseppe, et al. "Postprandial glucose control with different hybrid closed-loop systems according to type of meal in adults with type 1 diabetes." *Journal of Diabetes Science and Technology* 19.5 (2025): 1331-1340.

[26]- Vetrani, Claudia, et al. "Dietary determinants of postprandial blood glucose control in adults with type 1 diabetes on a hybrid closed-loop system." *Diabetologia* 65.1 (2022): 79-87.

[27]- Shalit, Roy, et al. "Unannounced meal challenges using an advanced hybrid closed-loop system." *Diabetes Technology & Therapeutics* 25.9 (2023): 579-588.

[28]- Royston, Chloë, et al. "Impact of ultra-rapid insulin on boost and ease-off in the Cambridge hybrid closed-loop system for individuals with type 1 diabetes." *Journal of Diabetes Science and Technology* (2024): 19322968241289963.

[29]- Haliloglu, Belma, et al. "Postprandial glucose excursions with ultra-rapid insulin analogs in hybrid closed-loop therapy for adults with type 1 diabetes." *Diabetes Technology & Therapeutics* 26.7 (2024): 449-456.

[30]- Ware, Julia, et al. "Hybrid closed-loop with faster insulin aspart compared with standard insulin aspart in very young children with type 1 diabetes: a double-blind, multicenter, randomized, crossover study." *Diabetes Technology & Therapeutics* 25.6 (2023): 431-436.

[31]- Grosman, Benyamin, et al. "Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMedTM 670G hybrid closed-loop system in simulated trials compared to NovoLog®." *Computer Methods and Programs in Biomedicine* 205 (2021): 106087.

[32]- Hsu, Liana, et al. "Fast-acting insulin aspart use with the MiniMedTM 670G system." *Diabetes technology & therapeutics* 23.1 (2021): 1-7.

[33]- Boughton, Charlotte K., et al. "Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: a double-blind, multicentre, multinational, randomized, crossover study." *Diabetes, Obesity and Metabolism* 23.6 (2021): 1389-1396.

[34]- Levy, Carol J., et al. "Multicenter evaluation of ultra-rapid lispro insulin with control-IQ technology in adults, adolescents, and children with type 1 diabetes." *Diabetes technology & therapeutics* 26.9 (2024): 652-660.

[35]- Cohen, Elisa, et al. "Simple meal announcements and pramlintide delivery versus carbohydrate counting in type 1 diabetes with automated fast-acting insulin aspart delivery: a randomised crossover trial in Montreal, Canada." *The Lancet Digital Health* 6.7 (2024): e489-e499.

[36]- Haidar, Ahmad, et al. "Reducing the need for carbohydrate counting in type 1 diabetes using closed-loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, non-inferiority, crossover pilot trial." *Diabetes, Obesity and Metabolism* 23.6 (2021): 1272-1281.

[37]- Breton, Marc, et al. "Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia." *Diabetes* 61.9 (2012): 2230-2237.

[38]- Turksoy, Kamuran, et al. "Multivariable adaptive closed-loop control of an artificial pancreas without meal and activity announcement." *Diabetes technology & therapeutics* 15.5 (2013): 386-400.

[39]- Breton, Marc D., et al. "Adding heart rate signal to a control-to-range artificial pancreas system improves the protection against hypoglycemia during exercise in type 1 diabetes." *Diabetes technology & therapeutics* 16.8 (2014): 506-511.

[40]- Turksoy, Kamuran, et al. "An integrated multivariable artificial pancreas control system." *Journal of diabetes science and technology* 8.3 (2014): 498-507.

[41]- Turksoy, Kamuran, et al. "An integrated multivariable artificial pancreas control system." *Journal of diabetes science and technology* 8.3 (2014): 498-507.

[42]- Castle, Jessica R., et al. "Randomized outpatient trial of single-and dual-hormone closed-loop systems that adapt to exercise using wearable sensors." *Diabetes care* 41.7 (2018): 1471-1477.

[43]- Jacobs, Peter G., et al. "Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy." *Diabetes, Obesity and Metabolism* 18.11 (2016): 1110-1119.

[44]- Jacobs, Peter G., et al. "Incorporating an exercise detection, grading, and hormone dosing algorithm into the artificial pancreas using accelerometry and heart rate." *Journal of diabetes science and technology* 9.6 (2015): 1175-1184.

[45]- Jacobs, Peter G., et al. "Integrating metabolic expenditure information from wearable fitness sensors into an AI-augmented automated insulin delivery system: a randomised clinical trial." *The Lancet Digital Health* 5.9 (2023): e607-e617.

[46]- Wilson, Leah M., et al. "Dual-hormone closed-loop system using a liquid stable glucagon formulation versus insulin-only closed-loop system compared with a predictive low glucose suspend system: an open-label, outpatient, single-center, crossover, randomized controlled trial." *Diabetes Care* 43.11 (2020): 2721-2729.

[47]- Sherr, Jennifer L., et al. "Reduced hypoglycemia and increased time in target using closed-loop insulin delivery during nights with or without antecedent afternoon exercise in type 1 diabetes." *Diabetes care* 36.10 (2013): 2909-2914.

[48]- Jayawardene, Dilshani C., et al. "Closed-loop insulin delivery for adults with type 1 diabetes undertaking high-intensity interval exercise versus moderate-intensity exercise: a randomized, crossover study." *Diabetes technology & therapeutics* 19.6 (2017): 340-348.

[49]- Lee, Melissa H., et al. "Glucose and counterregulatory responses to exercise in adults with type 1 diabetes and impaired awareness of hypoglycemia using closed-loop insulin delivery: a randomized crossover study." *Diabetes Care* 43.2 (2020): 480-483.

[50]- Seckold, Rowen, et al. "A comparison of glucose and additional signals for three different exercise types in adolescents with type 1 diabetes using a hybrid closed-loop system." *Diabetes Technology & Therapeutics* 27.4 (2025): 308-322.

[51]- Paldus, Barbora, et al. "Strengths and challenges of closed-loop insulin delivery during exercise in people with type 1 diabetes: potential future directions." *Journal of Diabetes Science and Technology* 17.4 (2023): 1077-1084.

[52]- Lei, Mengyun, et al. "The efficacy of glucose-responsive insulin and glucagon delivery on exercise-induced hypoglycaemia among adults with type 1 diabetes mellitus: A meta-analysis of randomized controlled trials." *Diabetes, Obesity & Metabolism* 26.4 (2024).

[53]- Moser, Othmar, et al. "The use of automated insulin delivery around physical activity and exercise in type 1 diabetes: a position statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD)." *Diabetologia* 68.2 (2025): 255-280.

[54]- Jacobs, Peter G., et al. "An evaluation of how exercise position statement guidelines are being used in the real world in type 1 diabetes: findings from the type 1 diabetes exercise initiative (T1DEXI)." *Diabetes Research and Clinical Practice* 217 (2024): 111874.

[55]- Frank, Spencer, et al. "Modeling the acute effects of exercise on insulin kinetics in type 1 diabetes." *Journal of pharmacokinetics and pharmacodynamics* 45.6 (2018): 829-845.

[56]- Nguyen, Thanh-Tin P., et al. "Separating insulin-mediated and non-insulin-mediated glucose uptake during and after aerobic exercise in type 1 diabetes." *American Journal of Physiology-Endocrinology and Metabolism* 320.3 (2021): E425-E437.

[57]- Young, Gavin M., et al. "Quantifying insulin-mediated and noninsulin-mediated changes in glucose dynamics during resistance exercise in type 1 diabetes." *American Journal of Physiology-Endocrinology and Metabolism* 325.3 (2023): E192-E206.

[58]- Alkhateeb, Haneen, et al. "Modelling glucose dynamics during moderate exercise in individuals with type 1 diabetes." *Plos one* 16.3 (2021): e0248280.

[59]- Romeres, Davide, et al. "Exercise effect on insulin-dependent and insulin-independent glucose utilization in healthy individuals and individuals with type 1 diabetes: a modeling study." *American Journal of Physiology-Endocrinology and Metabolism* (2021).

[60]- Hobbs, Nicole, et al. "A physical activity-intensity driven glycemic model for type 1 diabetes." *Computer Methods and Programs in Biomedicine* 226 (2022): 107153.

[61]- Ozaslan, Basak, et al. "Safety and feasibility evaluation of step count informed meal boluses in type 1 diabetes: a pilot study." *Journal of Diabetes Science and Technology* 16.3 (2022): 670-676.

[62]- Askari, Mohammad Reza, et al. "Meal and physical activity detection from free-living data for discovering disturbance patterns of glucose levels in people with diabetes." *BioMedInformatics* 2.2 (2022): 297-317.

[63]- Mosquera-Lopez, Clara, and Peter G. Jacobs. "Incorporating glucose variability into glucose forecasting accuracy assessment using the new glucose variability impact index and the prediction consistency index: An LSTM case example." *Journal of Diabetes Science and Technology* 16.1 (2022): 7-18.

[64]- Shetty, Vinutha B., et al. "Effect of exercise intensity on glucose requirements to maintain euglycemia during exercise in type 1 diabetes." *The Journal of Clinical Endocrinology & Metabolism* 101.3 (2016): 972-980.

[65]- Riddell, Michael C., et al. "Exercise and the development of the artificial pancreas: one of the more difficult series of hurdles." *Journal of diabetes science and technology* 9.6 (2015): 1217-1226.

[66]- Riddell, Michael C., and Anne L. Peters. "Exercise in adults with type 1 diabetes mellitus." *Nature Reviews Endocrinology* 19.2 (2023): 98-111.

[67]- Manrique, Camila, Guido Lastra, and James R. Sowers. "New insights into insulin action and resistance in the vasculature." *Annals of the New York Academy of Sciences* 1311.1 (2014): 138-150.

[68]- Mallad, Ashwini, et al. "Exercise effects on postprandial glucose metabolism in type 1 diabetes: a triple-tracer approach." *American Journal of Physiology-Endocrinology and Metabolism* 308.12 (2015): E1106-E1115.

[69]- Rickels, Michael R., et al. "Mini-dose glucagon as a novel approach to prevent exercise-induced hypoglycemia in type 1 diabetes." *Diabetes Care* 41.9 (2018): 1909-1916.

[70]- Taleb, Nadine, et al. "Efficacy of single-hormone and dual-hormone artificial pancreas during continuous and interval exercise in adult patients with type 1 diabetes: randomised controlled crossover trial." *Diabetologia* 59.12 (2016): 2561-2571.

[71]- Lundemose, Sissel Banner, et al. "Is low-dose glucagon needed and effective in preventing fasted exercise-induced hypoglycaemia in type 1 diabetes treated with the MiniMed 780G, an automated insulin delivery system?." *Diabetes, Obesity and Metabolism* 27.3 (2025): 1164-1171.

[72]- Hobbs, Nicole, et al. "Observational study of glycemic impact of anticipatory and early-race athletic competition stress in type 1 diabetes." *Frontiers in Clinical Diabetes and Healthcare* 3 (2022): 816316.

[73]- Morrison, Dale, et al. "Comparable glucose control with fast-acting insulin aspart versus insulin aspart using a second-generation hybrid closed-loop system during exercise." *Diabetes Technology & Therapeutics* 24.2 (2022): 93-101.

[74]- Askari, Mohammad Reza, et al. "Multivariable automated insulin delivery system for handling planned and spontaneous physical activities." *Journal of Diabetes Science and Technology* 17.6 (2023): 1456-1469.

[75]- Young, Gavin, et al. "Design and in silico evaluation of an exercise decision support system using digital twin models." (2024): 324-334.

[76]- O'Malley, Grenye, et al. "Longitudinal observation of insulin use and glucose sensor metrics in pregnant women with type 1 diabetes using continuous glucose monitors and insulin pumps: the LOIS-P study." *Diabetes technology & therapeutics* 23.12 (2021): 807-817.

[77]- Brown, Sue A., et al. "Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes." *New England Journal of Medicine* 381.18 (2019): 1707-1717.

[78]- García-Patterson, Apolonia, et al. "Insulin requirements throughout pregnancy in women with type 1 diabetes mellitus: three changes of direction." *Diabetologia* 53.3 (2010): 446-451.

[79]- Kampmann, Ulla, et al. "Determinants of maternal insulin resistance during pregnancy: an updated overview." *Journal of diabetes research* 2019.1 (2019): 5320156.

[80]- ElSayed, Nuha A., et al. "15. Management of diabetes in pregnancy: standards of care in diabetes—2023." *Diabetes care* 46.Supplement_1 (2023): S254-S266.

[81]- Marcinkevage, Jessica A., and KM Venkat Narayan. "Gestational diabetes mellitus: taking it to heart." *Primary Care Diabetes* 5.2 (2011): 81-88.

[82]- Ozaslan, Basak, et al. "Zone-MPC automated insulin delivery algorithm tuned for pregnancy complicated by type 1 diabetes." *Frontiers in Endocrinology* 12 (2022): 768639.

[83]- Feig, Denice S., et al. "Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial." *The Lancet* 390.10110 (2017): 2347-2359.

[84]- Feig, Denice S., et al. "Pumps or multiple daily injections in pregnancy involving type 1 diabetes: a prespecified analysis of the CONCEPTT randomized trial." *Diabetes Care* 41.12 (2018): 2471-2479.

[85]- Benhalima, Katrien, et al. "Automated insulin delivery for pregnant women with type 1 diabetes: where do we stand?." *Journal of diabetes science and technology* 18.6 (2024): 1334-1345.

[86]- Lawton, Julia, et al. "Listening to women: experiences of using closed-loop in type 1 diabetes pregnancy." *Diabetes Technology & Therapeutics* 25.12 (2023): 845-855.

[87]- Benhalima, Katrien, and Sarit Polsky. "Automated insulin delivery in pregnancies complicated by type 1 diabetes." (2025): 19322968251323614.

[88]- Yang, Kaijie, et al. "Global burden of type 1 diabetes in adults aged 65 years and older, 1990-2019: population based study." *Bmj* 385 (2024).

[89]- Munshi, Medha, et al. "Use of technology in older adults with type 1 diabetes: clinical characteristics and glycemic metrics." *Diabetes technology & therapeutics* 24.1 (2022): 1-9.

[90]- Munshi, Medha N., et al. "Continuous glucose monitoring with geriatric principles in older adults with type 1 diabetes and hypoglycemia: a randomized controlled trial." *Diabetes Care* 48.5 (2025): 694-702.

[91]- Beck, Roy W., et al. "A meta-analysis of randomized trial outcomes for the t: slim X2 insulin pump with control-IQ technology in youth and adults from age 2 to 72." *Diabetes Technology & Therapeutics* 25.5 (2023): 329-342.

[92]- Olsen, S. E., et al. "Hypoglycaemia symptoms and impaired awareness of hypoglycaemia in adults with type 1 diabetes: the association with diabetes duration." *Diabetic medicine* 31.10 (2014): 1210-1217.

[93]- Olsen, S. E., et al. "Hypoglycaemia symptoms and impaired awareness of hypoglycaemia in adults with type 1 diabetes: the association with diabetes duration." *Diabetic medicine* 31.10 (2014): 1210-1217.

[94]- Shah, Viral N., et al. "Severe hypoglycemia is associated with high risk for falls in adults with type 1 diabetes." *Archives of osteoporosis* 13.1 (2018): 66.

[95]- Shah, Viral N. "bone health in type 1 and type 2 diabetes: current knowledge and future direction." *Current Opinion in Endocrinology, Diabetes and Obesity* 28.4 (2021): 337-339.

[96]- Pratley, Richard E., et al. "Effect of continuous glucose monitoring on hypoglycemia in older adults with type 1 diabetes: a randomized clinical trial." *Jama* 323.23 (2020): 2397-2406.

[97]- Miller, Kellee M., et al. "Benefit of continuous glucose monitoring in reducing hypoglycemia is sustained through 12 months of use among older adults with type 1 diabetes." *Diabetes technology & therapeutics* 24.6 (2022): 424-434.

[98]- Boughton, Charlotte K., et al. "Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study." *The Lancet Healthy Longevity* 3.3 (2022): e135-e142.

[99]- Kudva, Yogish C., et al. "Automated insulin delivery in older adults with type 1 diabetes." *NEJM evidence* 4.1 (2025): EVIDoa2400200.

[100]- Daly, Aideen B., et al. "Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trial." *Nature medicine* 29.1 (2023): 203-208.

[101]- Borel, Anne-Laure, et al. "Closed-loop insulin therapy for people with type 2 diabetes treated with an insulin pump: a 12-week multicenter, open-label randomized, controlled, crossover trial." *Diabetes Care* 47.10 (2024): 1778-1786.

[102]- Bhargava, Anuj, et al. "Safety and Effectiveness of MiniMedTM 780G Advanced Hybrid Closed-Loop Insulin Intensification in Adults with Insulin-Requiring Type 2 Diabetes." *Diabetes Technology & Therapeutics* 27.5 (2025): 366-375.

[103]- Levy, Carol J., et al. "Beneficial effects of control-IQ automated insulin delivery in basal-bolus and basal-only insulin users with type 2 diabetes." *Clinical Diabetes* 42.1 (2024): 116-124.

[104]- Pasquel, Francisco J., et al. "Automated insulin delivery in adults with type 2 diabetes: A nonrandomized clinical trial." *JAMA Network Open* 8.2 (2025): e2459348-e2459348.

[105]- Fabris, Chiara, and Boris Kovatchev. "Real-life use of automated insulin delivery in individuals with type 2 diabetes." *Journal of Diabetes Science and Technology* (2024): 19322968241274786.

[106]- Forlenza, Gregory P., et al. "Real-world evidence supporting tandem control-IQ hybrid closed-loop success in the Medicare and Medicaid type 1 and type 2 diabetes populations." *Diabetes technology & therapeutics* 24.11 (2022): 814-823.

[107]- Chakrabarty, Ankush, et al. "Embedded model predictive control for a wearable artificial pancreas." *IEEE Transactions on Control Systems Technology* 28.6 (2019): 2600-2607.

[108]- Dassau, Eyal, et al. "Clinical evaluation of a personalized artificial pancreas." *Diabetes care* 36.4 (2013): 801-809.

[109]- Fushimi, Emilia, et al. "Artificial pancreas: Evaluating the ARG algorithm without meal announcement." *Journal of Diabetes Science and Technology* 13.6 (2019): 1035-1043.

[110]- Gondhalekar, Ravi, Eyal Dassau, and Francis J. Doyle III. "Velocity-weighting & velocity-penalty MPC of an artificial pancreas: Improved safety & performance." *Automatica* 91 (2018): 105-117.

[111]- Lee, Joon Bok, et al. "Enhanced model predictive control (eMPC) strategy for automated glucose control." *Industrial & engineering chemistry research* 55.46 (2016): 11857-11868.

[112]- Colmegna, Patricio, et al. "Automatic regulatory control in type 1 diabetes without carbohydrate counting." *Control engineering practice* 74 (2018): 22-32.

[113]- Shi, Dawei, Eyal Dassau, and Francis J. Doyle. "Adaptive zone model predictive control of artificial pancreas based on glucose-and velocity-dependent control penalties." *IEEE Transactions on Biomedical Engineering* 66.4 (2018): 1045-1054.

[114]- Dassau, Eyal, et al. "Twelve-week 24/7 ambulatory artificial pancreas with weekly adaptation of insulin delivery settings: effect on hemoglobin A1c and hypoglycemia." *Diabetes Care* 40.12 (2017): 1719-1726.

[115]- Cameron, Faye M., et al. "Closed-loop control without meal announcement in type 1 diabetes." *Diabetes technology & therapeutics* 19.9 (2017): 527-532.

[116]- Forlenza, Gregory P., et al. "Fully closed-loop multiple model probabilistic predictive controller artificial pancreas performance in adolescents and adults in a supervised hotel setting." *Diabetes technology & therapeutics* 20.5 (2018): 335-343.

[117]- Jacobs, Peter G., and Clara Mosquera-Lopez. "Artificial Intelligence in Automated Hormone Delivery." *Diabetes Digital Health, Telehealth, and Artificial Intelligence*. Academic Press, 2024. 329-340.

[118]- Moscoso-Vasquez, Marcela, et al. "Evaluation of an automated priming bolus for improving prandial glucose control in full closed loop delivery." *Diabetes Technology & Therapeutics* 27.2 (2025): 93-100.

[119]- Garcia-Tirado, Jose, et al. "Advanced closed-loop control system improves postprandial glycemic control compared with a hybrid closed-loop system following unannounced meal." *Diabetes Care* 44.10 (2021): 2379-2387.

[120]- Garcia-Tirado, Jose, et al. "Assessment of meal anticipation for improving fully automated insulin delivery in adults with type 1 diabetes." *Diabetes Care* 46.9 (2023): 1652-1658.

[121]- Boughton, Charlotte K., et al. "Fully closed-loop glucose control compared with insulin pump therapy with continuous glucose monitoring in adults with type 1 diabetes and suboptimal glycemic control: a single-center, randomized, crossover study." *Diabetes Care* 46.11 (2023): 1916-1922.

[122]- Boughton, Charlotte K., et al. "Implementation of fully closed-loop insulin delivery for inpatients with diabetes: real-world outcomes." *Diabetic Medicine* 40.6 (2023): e15092.

[123]- Dovc, Klemen, et al. "Faster compared with standard insulin aspart during day-and-night fully closed-loop insulin therapy in type 1 diabetes: a double-blind randomized crossover trial." *Diabetes Care* 43.1 (2020): 29-36.

[124]- Elian, Viviana, et al. "Risks and benefits of SGLT-2 inhibitors for type 1 diabetes patients using automated insulin delivery systems—a literature review." *International Journal of Molecular Sciences* 25.4 (2024): 1972.

[125]- Holmager, Pernille, et al. "GLP-1 receptor agonists in overweight and obese individuals with type 1 diabetes using an automated insulin delivery device: a real-world study." (2025): 286-291.

[126]- Shah, Viral N., et al. "Consensus report on glucagon-like peptide-1 receptor agonists as adjunctive treatment for individuals with type 1 diabetes using an automated insulin delivery system." *Journal of diabetes science and technology* 19.1 (2025): 191-216.

[127]- Sherr, Jennifer L., et al. "Mitigating meal-related glycemic excursions in an insulin-sparing manner during closed-loop insulin delivery: the beneficial effects of adjunctive pramlintide and liraglutide." *Diabetes care* 39.7 (2016): 1127-1134.

[128]- Tsoukas, Michael A., et al. "A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial." *The Lancet Digital Health* 3.11 (2021): e723-e732.

[129]- Van Bon, A. C., et al. "Bihormonal fully closed-loop system for the treatment of type 1 diabetes: a real-world multicentre, prospective, single-arm trial in the Netherlands." *The Lancet Digital Health* 6.4 (2024): e272-e280.

[130]- Tanenbaum, Molly L., et al. "‘We're taught green is good’: Perspectives on time in range and time in tight range from youth with type 1 diabetes, and parents of youth with type 1 diabetes." *Diabetic Medicine* 41.12 (2024): e15423.

[131]- Shah, Viral N., et al. "Time in range is associated with incident diabetic retinopathy in adults with type 1 diabetes: a longitudinal study." *Diabetes Technology & Therapeutics* 26.4 (2024): 246-251.

[132]- Lobo, Benjamin, et al. "The association of time-in-range and time-in-tight-range with retinopathy progression in the virtual diabetes control and complications trial continuous glucose monitoring dataset." *Diabetes Technology & Therapeutics* (2025).

[133]- Beck, Roy W., et al. "A comparison of continuous glucose monitoring-measured time-in-range 70–180 mg/dL versus time-in-tight-range 70–140 mg/dL." *Diabetes Technology & Therapeutics* 26.3 (2024): 151-155.

[134]- Mathieu, Chantal, et al. "The health economics of automated insulin delivery systems and the potential use of time in range in diabetes modeling: a narrative review." *Diabetes Technology & Therapeutics* 26.S3 (2024): 66-75.